Howard Capital Management Group LLC Sells 865 Shares of SPDR S&P Biotech ETF $XBI

Howard Capital Management Group LLC lessened its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 24.7% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 2,640 shares of the exchange traded fund’s stock after selling 865 shares during the period. Howard Capital Management Group LLC’s holdings in SPDR S&P Biotech ETF were worth $219,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. grew its holdings in SPDR S&P Biotech ETF by 33.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 13,524,858 shares of the exchange traded fund’s stock worth $1,096,866,000 after acquiring an additional 3,353,029 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of SPDR S&P Biotech ETF by 625.1% during the first quarter. JPMorgan Chase & Co. now owns 10,369,706 shares of the exchange traded fund’s stock valued at $840,983,000 after purchasing an additional 12,344,558 shares during the last quarter. Bessemer Group Inc. grew its stake in shares of SPDR S&P Biotech ETF by 4.0% during the first quarter. Bessemer Group Inc. now owns 1,432,066 shares of the exchange traded fund’s stock valued at $116,141,000 after purchasing an additional 55,232 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of SPDR S&P Biotech ETF during the first quarter valued at approximately $85,155,000. Finally, Hsbc Holdings PLC grew its stake in shares of SPDR S&P Biotech ETF by 2.7% during the first quarter. Hsbc Holdings PLC now owns 819,267 shares of the exchange traded fund’s stock valued at $65,379,000 after purchasing an additional 21,804 shares during the last quarter.

SPDR S&P Biotech ETF Stock Performance

Shares of XBI opened at $97.95 on Friday. The business’s fifty day moving average price is $90.67 and its two-hundred day moving average price is $84.67. The firm has a market capitalization of $5.33 billion, a price-to-earnings ratio of 11.47 and a beta of 0.97. SPDR S&P Biotech ETF has a 52 week low of $66.66 and a 52 week high of $105.47.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.